Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06647017

Delivering Transcutaneous Auricular Neurostimulation to Reduce Blood Loss During Dialysis AV Graft Placement Procedures

The objective of this study is to determine if tAN therapy can reduce the volume of blood lost during dialysis AV graft placement procedures.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University Surgical Vascular

Watkinsville, Georgia, 30677, United States

Location status: Recruiting

Location contact

David Sailors, MD

CONTACT

David Sailors, MD

PRINCIPAL_INVESTIGATOR

About this study

This study is designed as a randomized, double-blind, sham-controlled, single-center, pilot clinical trial in which adults undergoing dialysis port placement procedures will be randomized 1:1 into one of two treatment groups:

Group 1: Active tAN + standard of care Group 2: Sham tAN + standard of care

Participants will receive 30 minutes of active or sham tAN immediately prior to the dialysis port placement procedure. Blood loss and blood markers will be measured before and during the procedure to measure the effect of the therapy.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Participant is undergoing a dialysis port placement procedure using synthetic graft
  • Participant is between 18 and 75 years of age
  • Participant is English proficient
  • Participant is able to provide informed consent and function at an intellectual level sufficient for study requirements

Exclusion criteria

  • Participant has a BMI ≥ 40
  • Participant is currently taking a platelet inhibitor medication
  • Participant has a history of epileptic seizures
  • Participant has a history of neurological diseases or traumatic brain injury
  • Participant has presence of devices, e.g., pacemakers, cochlear prosthesis, neurostimulators
  • Participant has abnormal ear anatomy or ear infection present
  • Person of childbearing age, not using adequate contraception as per investigator judgment or not willing to comply with contraception for the duration of the study
  • Person who is pregnant or lactating
  • Participant has any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant's ability to participate in the trial

Treatment and study plan

Volta tAN System

Device

Transcutaneous auricular neurostimulation (tAN)

Other names: Sparrow Ascent

SHAM Volta tAN System

Device

Participants randomized to the sham group will have an earpiece applied, but stimulation will not be turned on.

Other names: Sparrow Ascent

Primary outcomes

  1. Mean Total Blood Loss

    Time frame: Throughout procedure

    Comparison of mean total quantified blood loss in active tAN versus sham tAN groups.

Secondary outcomes

  1. Surgery Time

    Time frame: First incision to incision closure

    Surgery time measured as total time from first incision to incision closure in active tAN versus sham tAN groups.

  2. Time to Hemostasis

    Time frame: From end of AV graft placement to beginning of surgical site closure

    Comparison of mean time to hemostasis in active tAN versus sham tAN groups.

Other outcomes

  1. Hemostatic Agent Use

    Time frame: During surgery

    Proportion of participants requiring hemostatic agents

  2. Duration of time between completing graft placement and application/administration of hemostatic agent

    Time frame: During surgery

    Duration of time between completing graft placement and application/administration of hemostatic agent

  3. Proportion of participants achieving hemostasis in <10 minutes

    Time frame: During surgery

    Proportion of participants achieving hemostasis in <10 minutes

  4. Blood Assay Results

    Time frame: Prior to device placement, during surgery, and at end of surgery

    Blood urea nitrogen (BUN) levels, platelet count, hematocrit, and activated clotting time (ACT)

  5. Treatment-Related Adverse Events (Safety)

    Time frame: Thorough study completion, an average of 4 hours

    The proportion of participants who experience one or more treatment-related adverse events.

Study contacts

Contact information is provided by the study sponsor or research team.

David Sailors, MD

CONTACT

[email protected]

(706) 549-8306

Sponsors and collaborators

Lead sponsor

University Surgical Vascular

Industry

Collaborators

  • Spark Biomedical, Inc.

Registry information

Important dates

Study start
2024
Primary completion
2026
Study completion
2026
First posted
Oct 17, 2024
Registry last updated
May 8, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.